HC Wainwright Forecasts Lower Earnings for PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) – HC Wainwright decreased their FY2026 earnings estimates for PDS Biotechnology in a research note issued to investors on Tuesday, September 8th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.49) per share for the year, down from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q4 2026 earnings at ($0.09) EPS, FY2027 earnings at ($0.30) EPS and FY2028 earnings at ($0.23) EPS.

Several other research firms have also weighed in on PDSB. Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Stock Up 7.6%

Shares of PDS Biotechnology stock opened at $0.32 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.57 and a debt-to-equity ratio of 2.73. PDS Biotechnology has a 12 month low of $0.20 and a 12 month high of $1.55. The business has a fifty day simple moving average of $0.51 and a 200 day simple moving average of $0.78. The stock has a market cap of $17.65 million, a PE ratio of -0.49 and a beta of 1.46.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05).

Institutional Trading of PDS Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of PDSB. Armistice Capital LLC bought a new position in PDS Biotechnology in the fourth quarter valued at approximately $2,182,000. BlackRock Inc. acquired a new stake in shares of PDS Biotechnology in the 2nd quarter valued at approximately $535,000. Geode Capital Management LLC grew its stake in shares of PDS Biotechnology by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after buying an additional 38,399 shares in the last quarter. Squarepoint Ops LLC increased its holdings in PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after buying an additional 156,662 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in PDS Biotechnology by 25.0% during the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after acquiring an additional 44,100 shares in the last quarter. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.